TH
ESPR

Transmarket Holdings’s Esperion Therapeutics ESPR Stock Holding History

Transmarket Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03M Buy
+1,590,721
New +$4.45M 3.69% 12

Other funds holding ESPR

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Transmarket Holdings's ESPR Position: Q2 2026 in Review

Transmarket Holdings opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,590,721 shares worth $5.03M. The stake represents 3.69% of the portfolio and ranks #12 among its holdings.

27 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Transmarket Holdings held 1,590,721 shares of Esperion Therapeutics worth $5.03M as of Q2 2026.
  • Esperion Therapeutics was a new Transmarket Holdings position in Q2 2026.
  • Esperion Therapeutics made up 3.69% of Transmarket Holdings's portfolio in Q2 2026, its #12 holding.
  • 27 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Transmarket Holdings's 13F filing for Q2 2026, filed 21 Jul 2026.